Drug intelligence / Profile preview

SAP003

Development stage: Phase 1
Lead developer: Sapu Nano
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

SAP003 is an intravenous formulation of everolimus, developed by Sapu Nano, a joint venture between Oncotelic Therapeutics and Dragon Oversea. It utilizes Deciparticle technology, leveraging nanomedicines to overcome the limitations of oral mTOR inhibitors. SAP003 is currently in a Phase 1 clinical trial for the treatment of breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET).

Other names: everolimus Deciparticleintravenous everolimus DeciparticleIV everolimus Deciparticle

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on SAP003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAP003.

Explore the full profile